학술논문
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Document Type
article
Author
Panagiotis A. Konstantinopoulos; Alexandre André B. A. da Costa; Doga Gulhan; Elizabeth K. Lee; Su-Chun Cheng; Andrea E. Wahner Hendrickson; Bose Kochupurakkal; David L. Kolin; Elise C. Kohn; Joyce F. Liu; Elizabeth H. Stover; Jennifer Curtis; Nabihah Tayob; Madeline Polak; Dipanjan Chowdhury; Ursula A. Matulonis; Anniina Färkkilä; Alan D. D’Andrea; Geoffrey I. Shapiro
Source
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
A randomized phase 2 study recently showed that the addition of ATR inhibitor berzosertib to gemcitabine improved PFS compared to gemcitabine alone in patients with ovarian cancer. In this preplanned exploratory study, the authors demonstrate that a genomic biomarker of replication-stress is associated with outcome to gemcitabine alone and may predict which patients benefit from addition of the ATR inhibitor berzosertib.